Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04500665 · ClinicalTrials.gov registry record · Phase 2

Anti-Inflammatory Treatment of Uremic Cardiomyopathy With Colchicine

A Phase 2 study of Chronic Kidney Diseases, sponsored by Brigham and Women's Hospital.

Recruiting
Registry status
Phase 2
Development phase
20
Enrollment target
1
Study location

NCT04500665 is a Phase 2 study of Chronic Kidney Diseases that is actively recruiting participants, run by Brigham and Women's Hospital. The registered enrollment target is 20 participants, below the 445-participant average among 73 other Chronic Kidney Diseases trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04500665, a Phase 2 study of Chronic Kidney Diseases, is actively recruiting participants, sponsored by Brigham and Women's Hospital.

RECRUITING
Registry status
Phase 2
Development phase
20 participants
Enrollment target
1
Study location

Study Summary

This study is designed to determine the efficacy and safety of colchicine in patients with chronic kidney disease.

Conditions Studied

Interventions

  • DRUG Placebo
  • DRUG Colchicine

Study Locations (1)

Massachusetts

  • Brigham and Women's Hospital - Boston

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2021-11-01
Est. Completion 2026-11-11
Phase Phase 2

Sponsor

Brigham and Women's Hospital

937 total trials

What the Registry Record Tells You About NCT04500665

The ClinicalTrials.gov registry entry for NCT04500665 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 445-participant average among 73 other Chronic Kidney Diseases trials with a reported enrollment target (96% lower). The listed sponsor is Brigham and Women's Hospital, which has 937 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Chronic Kidney Diseases appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT04500665 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.

Frequently Asked Questions

What is clinical trial NCT04500665 about?

NCT04500665 is a clinical study titled "Anti-Inflammatory Treatment of Uremic Cardiomyopathy With Colchicine". This study is designed to determine the efficacy and safety of colchicine in patients with chronic kidney disease.

What is the current status of trial NCT04500665?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2021-11-01. Estimated completion is 2026-11-11.

What conditions does trial NCT04500665 study?

This clinical trial studies the following conditions: Chronic Kidney Diseases.

What interventions are being tested in trial NCT04500665?

The interventions under investigation include: Placebo (DRUG), Colchicine (DRUG).

Who is sponsoring clinical trial NCT04500665?

This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04500665 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Chronic Kidney Diseases

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.